Robert Chess - Sep 22, 2021 Form 4 Insider Report for NEKTAR THERAPEUTICS (NKTR)

Role
Director
Signature
Mark A. Wilson, Attorney-in-Fact
Stock symbol
NKTR
Transactions as of
Sep 22, 2021
Transactions value $
-$82,524
Form type
4
Date filed
9/24/2021, 06:13 PM
Previous filing
Sep 14, 2021
Next filing
Oct 21, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NKTR Common Stock Award $0 +10.2K +3.72% $0.00 284K Sep 22, 2021 Direct F1, F2
transaction NKTR Common Stock Sale -$82.5K -4.6K -1.62% $17.94 280K Sep 22, 2021 Direct F3, F4
holding NKTR Common Stock 2.1K Sep 22, 2021 by daughter F5
holding NKTR Common Stock 2.1K Sep 22, 2021 by son F5
holding NKTR Common Stock 2.1K Sep 22, 2021 by daughter F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NKTR Stock Option Award $0 +20.4K $0.00 20.4K Sep 22, 2021 Common Stock 20.4K $17.78 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock.
F2 This RSU award vests in full, one year following September 22, 2021.
F3 This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F4 This transaction was executed in multiple trades at prices ranging from $17.59 to $18.28. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issues.
F5 The reporting person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose.
F6 This stock option vests in equal monthly installments over the one-year period beginning on September 22, 2021.